*Department of Laboratory Medicine and Pathology
††Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
†Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD
‡Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA
§Division of Hematopathology, University of Pittsburgh Medical Center, Pittsburgh, PA
∥Department of Pathology and Laboratory Medicine, United Health Services Hospitals, Johnson City/Binghamton
#Department of Pathology and Laboratory Medicine, Centrex Clinical Laboratories, Utica, NY
¶Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH
**Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL
‡‡Department of Pathology, Duke University, Durham, NC
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.ajsp.com.
Conflicts of Interest and Source of Funding: Supported by Award Numbers R01 CA177734 (A.L.F.) and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute, by Award Number UL1 TR000135 (Mayo Clinic CTSA) from the National Center for Advancing Translational Science, and by the Predolin Foundation. S.H.S. has accepted a speaker honorarium and meeting travel expenses from Chugai Pharmaceutical Co. E.D.H. has received a speaker honorarium from Seattle Genetics and sponsored research support from Abbvie, Eli Lilly, and Cellerant Therapeutics. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Andrew L. Feldman, MD, Department of Laboratory Medicine and Pathology, Hilton Building, Room 8-00F, Mayo Clinic, 200 First St. SW, Rochester, MN 55905 (e-mail: [email protected]).